This week, Pharmacy Choice published an announcement that patient enrollment has begun in the RECITAL (A Patient Registry Evaluating Closure Following Access with the Arstasis One Access System) Study. The non-randomized, prospective, post-approval study anticipates enrolling up to 500 patients in at least seven U.S. hospitals including Cooper. The goal of the study is to observe the clinical safety and effectiveness of the Arstasis One Access System in patients undergoing diagnostic angiography procedures through the femoral artery.
“The Arstasis One femoral artery access system marks the beginning of a new approach to heart catheterization,” commented Zoltan G. Turi, MD, Director, Vascular Center at Cooper and the national principal investigator of the RECITAL study. “We hope to show that patients who participate in this study benefit from femoral artery closure that has advantages over regular manual compression.”